Cargando…
XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: Suitability as a biomarker for patient selection
As the options for systemic treatment of malignant melanoma (MM) increase, the need to develop biomarkers to identify patients who might benefit from cytotoxic chemotherapy becomes more apparent. In preclinical models, oxaliplatin has activity in cisplatin-resistant cells. In this study, we have sho...
Autores principales: | Hatch, Stephanie B, Swift, Lonnie P, Caporali, Simona, Carter, Rebecca, Hill, Esme J, MacGregor, Thomas P, D’Atri, Stefania, Middleton, Mark R, McHugh, Peter J, Sharma, Ricky A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233955/ https://www.ncbi.nlm.nih.gov/pubmed/23982883 http://dx.doi.org/10.1002/ijc.28454 |
Ejemplares similares
-
Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma
por: MacGregor, T. P., et al.
Publicado: (2018) -
XPF–ERCC1: Linchpin of DNA crosslink repair
por: McHugh, Peter J.
Publicado: (2020) -
Neuropilin-1 expressing melanoma cells as a model to study the aggressiveness of metastatic melanoma
por: Ruffini, Federica, et al.
Publicado: (2015) -
Platelet-derived growth factor-C promotes human melanoma aggressiveness through activation of neuropilin-1
por: Ruffini, Federica, et al.
Publicado: (2017) -
XPF–ERCC1 Blocker Improves the Therapeutic Efficacy of 5-FU- and Oxaliplatin-Based Chemoradiotherapy in Colorectal Cancer
por: Huang, Ming-Yii, et al.
Publicado: (2023)